A Sun Pharmaceutical plant in India that has been repeatedly cited by the FDA for serious quality control issues failed ...

India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Trump pharma and chip tariffs may start this month, sparking price hikes, inflation, and global trade ripples.

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

Stay updated with the Sun Pharma Stock Liveblog, your one-stop destination for real-time information and analysis of a leading stock. Explore the latest updates on Sun Pharma stock, including: Last ...

Sun Pharmaceutical Industries Ltd. closed 14.19% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

The drug is indicated for the treatment of alopecia areata - a condition in which the immune system attacks hair follicles, ...

U.S. inspectors have found new breakdowns at a Sun Pharmaceuticals plant in India that produces medications for U.S. customers, ProPublica reported July 16. The FDA found the factory failed to ...